Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Affiliation
Department of Surgery, Cork University Hospital, Wilton, Cork, Ireland., nnc1@eircom.netIssue Date
2012-02-03T15:06:34ZMeSH
AnimalsAutoimmunity/*immunology
Humans
Neoplasms/*immunology
T-Lymphocytes, Regulatory/*immunology
Transplantation Immunology/*immunology
Metadata
Show full item recordCitation
J Surg Res. 2006 Jan;130(1):124-35. Epub 2005 Sep 8.Journal
The Journal of surgical researchDOI
10.1016/j.jss.2005.07.033PubMed ID
16154142Abstract
Approximately 20% of the population is affected by autoimmune or inflammatory diseases mediated by an abnormal immune response. A characteristic feature of autoimmune disease is the selective targeting of a single cell type, organ or tissue by certain populations of autoreactive T-cells. Examples of such diseases include rheumatoid arthritis, insulin-dependent diabetes mellitus, and systemic lupus erythematosus (SLE), all of which are characterized by chronic inflammation, tissue destruction and target organ malfunction. Although strong evidence links most autoimmune diseases to specific genes, considerable controversy prevails regarding the role of regulatory T-cell populations in the disease process. These cells are now also believed to play a key role in mediating transplantation tolerance and inhibiting the induction of tumor immunity. Though the concept of therapeutic immune regulation aimed at treating autoimmune pathology has been validated in many animal models, the development of strategies for the treatment of human autoimmune disorders remains in its infancy. The main obstacles to this include the conflicting findings of different model systems, as well as the contrasting functions of regulatory T-cells and cytokines involved in the development of such disorders. This review examines the role of regulatory T-cells in the pathogenesis of autoimmunity and describes the therapeutic potential of these cells for the prevention of immune-mediated pathologies in the future. Although much remains to be learned about such pathologies, a clearer understanding of the mechanisms by which regulatory T-cells function will undoubtedly lead to exciting new possibilities for immunotherapeutics.Language
engISSN
0022-4804 (Print)0022-4804 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1016/j.jss.2005.07.033
Scopus Count
Collections
Related articles
- Regulatory T cells--the renaissance of the suppressor T cells.
- Authors: Bopp T, Jonuleit H, Schmitt E
- Issue date: 2007
- Animal models of endocrine/organ-specific autoimmune diseases: do they really help us to understand human autoimmunity?
- Authors: Lam-Tse WK, Lernmark A, Drexhage HA
- Issue date: 2002 Dec
- Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
- Authors: Hess AD
- Issue date: 2006 Jan
- Therapeutic modulation of cutaneous autoimmunity by regulatory T cells.
- Authors: Loser K, Beissert S
- Issue date: 2006 Oct
- CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.
- Authors: Kuhn A, Beissert S, Krammer PH
- Issue date: 2009 Jan